<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04879940</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-20832</org_study_id>
    <nct_id>NCT04879940</nct_id>
  </id_info>
  <brief_title>Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization</brief_title>
  <official_title>Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization in Patients With Localized Prostate Carcinoma and Obstructive Lower Urinary Tract Symptoms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase II prospective clinical trial in which patients with prostate carcinoma and&#xD;
      obstructive lower urinary tract symptoms electing for radiation therapy will undergo&#xD;
      Prostatic Artery Embolization (PAE) prior to treatment. PAE will be administered by&#xD;
      Interventional Radiology. Patients will be seen for follow-up at 6 weeks and 12 weeks&#xD;
      following PAE after which they will start definitive radiotherapy. After completion of&#xD;
      radiotherapy the patient will be seen at 12 weeks&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 18, 2021</start_date>
  <completion_date type="Anticipated">August 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in International Prostate Symptom Score</measure>
    <time_frame>At screening, Day of PAE, and 6 weeks &amp; 12 weeks after PAE</time_frame>
    <description>Participants will take quality of life questionnaires including the International Prostate Symptom Score (IPSS)questionnaire to determine changes in prostate symptoms. Questionnaire will be taken at screening, Day 0- day of prostatic artery embolization (PAE), and at 6 weeks and 12 weeks after PAE. The IPSS asks the patient to rate urinary symptoms on a scale of 0-5, 0 indicating the participant has not had a symptom at all, and 5 indicating the symptom &quot;almost always&quot;.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prostate Volume Reduction after PAE</measure>
    <time_frame>At 12 weeks</time_frame>
    <description>Prostate volume will be determined by MRI prior to PAE and at 12 weeks post PAE to determine changes in volume.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in American Urologic Association Score</measure>
    <time_frame>At 18 weeks</time_frame>
    <description>Participants will take quality of life questionnaires including the American Urologic Association (AUA) test to assess genitourinary toxicity after PAE and radiation therapy. The AUA questionnaire asks the patient to rate urinary symptoms on a scale of 0-5, 0 indicating indicating the participant has not had a symptom at all, and 5 indicating the symptom &quot;almost always&quot;.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Prostate Carcinoma</condition>
  <condition>Benign Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>Prostatic Artery Embolization (PAE)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who receive PAE with Merit Medical Embospheres.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Merit Medical Embospheres</intervention_name>
    <description>Prostatic Artery Embolization will performed as an outpatient procedure in Interventional Radiology. Bilateral selective pelvic angiograms will be performed to localize the prostatic arteries. Cone-beam or 3D computed tomography (CT) will be performed prior to embolization, if technically feasible and necessary. Embolization will be performed using Merit Medical Embospheres.</description>
    <arm_group_label>Prostatic Artery Embolization (PAE)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation Therapy</intervention_name>
    <description>Patients will undergo standard of care definitive radiation therapy.</description>
    <arm_group_label>Prostatic Artery Embolization (PAE)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed prostate adenocarcinoma in the very low or&#xD;
             low risk risk stratification groups (i.e. Grade group 1 or Gleason score ≤ 6) and&#xD;
             eligible for radiation therapy.&#xD;
&#xD;
          -  Ability to receive prostatic artery embolization within 6-12 weeks of definitive&#xD;
             radiation therapy.&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document&#xD;
&#xD;
          -  Prostate larger than 60 grams but less than 150 grams, as assessed by imaging scans&#xD;
&#xD;
          -  American Urologic Association (AUA) or International Prostate Symptom Score (IPSS)&#xD;
             Score ≥ 15&#xD;
&#xD;
          -  Normal organ and marrow function as defined in protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Receiving androgen deprivation therapy (ADT)&#xD;
&#xD;
          -  Patients with intermediate (Gleason Grade Groups 2 and 3) or high risk localized PCa&#xD;
             (Gleason Grade Groups 4 and 5)&#xD;
&#xD;
          -  Receiving any investigational agents for the explicit purpose of prostatic size&#xD;
             reduction&#xD;
&#xD;
          -  Inability to receive prostatic artery embolization (PAE) within 6-12 weeks of&#xD;
             definitive radiation therapy&#xD;
&#xD;
          -  Active urinary tract infection (UTI)&#xD;
&#xD;
          -  History of severe allergic reaction to intravenous contrast media (iodinated and&#xD;
             gadolinium- based) or any agents used during the PAE; patient cannot be medicated&#xD;
             against allergic reaction prior to PAE.&#xD;
&#xD;
          -  Active cystolithiasis or prostatitis&#xD;
&#xD;
          -  Inability to have multi-parametric magnetic resonance imaging (mpMRI)&#xD;
&#xD;
          -  Prior transurethral resection of the prostate (TURP) within 2 years&#xD;
&#xD;
          -  Prostate size greater than or equal to150 grams&#xD;
&#xD;
          -  Vulnerable subjects (e.g., inmates and developmentally delayed adults) who are&#xD;
             subjects for whom the study may be unsafe or whose rights may be violated with&#xD;
             enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>male</gender_description>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nainesh S Parikh, MD, MBA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Moffitt Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cassie Nesbit</last_name>
    <phone>813-745-4070</phone>
    <email>Cassie.Nesbit@moffitt.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cassie Nesbit</last_name>
      <phone>813-745-4070</phone>
      <email>Cassie.Nesbit@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Nainesh S Parikh, MD, MBA</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julio Pow Sang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Poch, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brandon Manley, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kosj Yamoah, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Javier F Torres-Roca, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter A Johnstone, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Grass, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.moffitt.org/research--clinical-trials/clinical-trials</url>
    <description>Moffitt Cancer Center Clinical Trials website</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 5, 2021</study_first_submitted>
  <study_first_submitted_qc>May 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 10, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

